Comparison of nephron-protective effects of enalapril and glp analogues (exenatide) in diabetic nephropathy

Experimental and Clinical Endocrinology and Diabetes

Volumn 122, Issue 6, 2014, Pages 327-333

  Cavusoglu T ^a   Erbas, O ^b   Karadeniz, T ^c   Akdemir, O ^d   Acikgoz, E ^d   Karadeniz, M ^e   Tuglu, M I ^f   Ates, U ^a  

^a Faculty of Medicine   (Turkey)

^b Medicine Faculty Department of Physiology University of Tokat   (Turkey)

^c Izmir Tepecik Training and Research Hospital   (Turkey)

^d Istanbul Medicalpark Hospital   (Turkey)

^e SIFA UNIVERSITY   (Turkey)

^f CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

biochemical; diabetes; enalapril; exenatide; histopathological; medicine

Indexed keywords

CREATININE; ENALAPRIL; EXENDIN 4; FIBRONECTIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; SERVIER; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; NOS2 PROTEIN, RAT; PEPTIDE; VENOM;

ANALYTICAL EQUIPMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOANALYZER; BRUSH BORDER; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DILATATION; DISSOCIATION; DRUG EFFECT; GLOMERULAR STRUCTURE; GLOMERULUS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVESTIGATIVE PROCEDURES; KIDNEY PARENCHYMA; KIDNEY TUBULE EPITHELIUM; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; TREATMENT RESPONSE; TUBULAR DILATATION; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINE DIPSTICK; ANIMAL; BIOSYNTHESIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; NEPHRON; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; ENALAPRIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYPOGLYCEMIC AGENTS; MALE; NEPHRONS; NITRIC OXIDE SYNTHASE TYPE II; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; VENOMS;

EID: 84902685768     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1372584     Document Type: Article

References (59)

1. Gross J. L., de Azevedo M. J., Silveiro S. P. et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care: 2005; 28 164 176 (Pubitemid 40095801)
2. Chaturvedi N., Bandinelli S., Mangili R. et al. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int: 2001; 60 219 227 (Pubitemid 32587557)
3. Adler A. I., Stevens R. J., Manley S. E. et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int: 2003; 63 225 232
4. Parving H. H., Hommel E., Mathiesen E. et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed): 1988; 296 156
5. Nieuwdorp M., van Haeften T. W., Gouverneur M. et al. Loss of endothelial glycocalyx during acute hyperglycemia. Diabetologia: 2008; 51 714 725
6. Weir M. R. Differing effects of antihypertensive agents on urinary albumin excretion. Am J Nephrol: 1996; 16 237 245 (Pubitemid 26133564)
7. Salvetti A., Mattei P., Sudano I. Renal protection and antihypertensive drugs. Drugs: 1999; 57 665 693
8. Lacourcière Y., Nadeau A., Poirier L. et al. Captopril or conventional therapy in hypertensive type II diabetics: Three year analysis. Hypertension: 1993; 21 786 794 (Pubitemid 23171641)
9. Sano T., Kawamura T., Matsumae H. et al. Effects of long-term enalapril treatment on persistent microalbuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care: 1994; 17 420 424 (Pubitemid 24145216)
10. Leoncini G., Viazzi F., Pontremoli R. Chronic kidney disease and albuminuria in arterial hypertension. Curr Hypertens Rep: 2010; 12 335 341
11. Elrick H., Stimmler L., Hlad C. J. Jr et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab: 1964; 24 1076 1082
12. Raufman J. P., Singh L., Singh G. et al. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem: 1992; 267 21432 21437
13. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA: 1992; 89 8641 8645
14. Ban K., Noyan A., Shraf M. H. et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation: 2008; 117 2340 2350 (Pubitemid 351653542)
15. Park C. W., Kim H. W., Ko S. H. et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol: 2007; 18 1227 1238 (Pubitemid 46536909)
16. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Research and Clinical Practice: 2010; 90 131 140
17. Yang J., Zeng Z., Wu T. et al. Emodin attenuates high glucose-induced TGF-β1and fibronectin expression in mesangialcells through inhibition of NF-κB pathway. Exp Cell Res: 2013; 319 3182 3189
18. Jackson B., Cubela R., Debrevi L. et al. Disparate effects of angiotensin converting enzyme inhibitor and calcium blocker treatment on the preservation of renal structure and function following subtotal nephrectomy or streptozotocin-induced diabetes in the rat. J Cardiovasc Pharmacol: 1987; 10 167 169
19. Hu G., Zhang Y., Jiang H. et al. Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression. Cardiol J: 2013; 20 600 604
20. nd (ed.). St. Louis, MO Mosby: 2002; 811 880
21. Simerville J. A., Maxted W. C., Pahira J. J. Urinalysis: a comprehensive review [published correction appears in Am Fam Physician. 2006; 74: 1096]. Am Fam Physician: 2005; 71 1153 1162
22. Pietrow P. K., Karellas M. E. Medical management of common urinary calculi. Am Fam Physician: 2006; 74 86 94 (Pubitemid 44049737)
23. Grossfeld G. D., Wolf J. S. Jr, Litwan M. S. et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician: 2001; 63 1145 1154 (Pubitemid 32238876)
24. Epstein M., Sowers J. R. Diabetes mellitus and hypertension. Hypertension: 1992; 19 403 418
25. The National High Blood Pressure Education Program Working Group National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension: 1994; 23 145 158
26. Hannedouche T., Landais P., Goldfarb B. et al. Randomized controlled trial of enalapril and beta blockers in nondiabetic chronic renal failure. BMJ: 1994; 309 833 837 (Pubitemid 24305005)
27. Kamper A. L., Strandgaard S., Leyssac P. P. Effect of enalapril on the progression of chronic renal failure: a randomized controlled trial. Am J Hypertens: 2002; 5 423 430
28. Maschio G., Alberti D., Janin G. et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med: 1996; 334 939 945 (Pubitemid 26114159)
29. Akishita M., Nagai K., Xi H. et al. Renin-angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats. Hypertension: 2005; 45 1188 1193 (Pubitemid 40770325)
30. Zafari A. M., Ushio-Fukai M., Akers M. et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension: 1998; 32 488 495 (Pubitemid 28429138)
31. Vaziri N. D., Ni Z., Oveisi F. et al. Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension: 2000; 36 957 964
32. Vaziri N. D., Ding Y., Ni Z. Compensatory up-regulation of nitric oxide synthase isoforms in lead-induced hypertension; reversal by a superoxide dismutase-mimetic drug. J Pharmacol Exp Ther: 2001; 298 679 685 (Pubitemid 32673420)
33. Broadbent N. V., Stahl P. J., Chen J. et al. Early upregulation of iNOS mRNA expression and increase in NO metabolites in pressurized renal epithelial cells. Am J Physiol Renal Physiol: 2007; 293 1877 1888
34. Sharma R., Sharma M., Reddy S. et al. Chronically increased intrarenal angiotensin II causes nephropathy in an animal model of type 2 diabetes. Front Biosci: 2006; 1; 11 968 976 (Pubitemid 43253451)
35. Comper W. D., Hilliard L. M., Nikolic-Paterson D. J. et al. Disease-dependent mechanisms of albuminuria. American Journal of Physiology: 2008; 295 1589 1600
36. Ciechanowicz A. Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure. Ann Acad Med Stetin: 1999; 52 1 93
37. Noh H., Ha H., Yu M. R. et al. High glucose increases inducible NO production in cultured rat mesangial cells. Possible role in fibronectin production. Nephron: 2002; 90 78 85 (Pubitemid 34042845)
38. Liu X. H., Wang Y. P., Wang L. X. et al. Exendin-4 protects murine MIN6 pancreatic β-cells from interleukin-1β-induced apoptosis via the NF-κB pathway. J Endocrinol Invest: 2013; 18
39. Hocher B., Reichetzeder C., Alter M. L. Renal and cardiac effects of DPP4 inhibitors-from preclinical development to clinical research. Kidney & Blood Pressure Research: 2012; 36 65 84
40. Lazzara M. J., Deen W. M. Model of albumin reabsorption in the proximal tubule. American Journal of Physiology: 2007; 292 430 439
41. Satchell S. C., Tooke J. E. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia: 2008; 51 714 725
42. Nieuwdorp M., van Haeften T. W., Gouverneur M. C. et al. Loss of endothelial glycocalyx during acute hyperglycemia. Diabetologia: 2008; 51 714 725
43. Lemley K. V., Blouch K., Abdullah I. et al. Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. Journal of the American Society of Nephrology: 2000; 11 2095 2105
44. Pavenstädt H., Kriz W., Kretzler M. Cell biology of the glomerular podocyte. Physiological Reviews: 2003; 83 253 307 (Pubitemid 36459882)
45. Bullock B. P., Heller R. S., Habener J. F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology: 1996; 137 2968 2978 (Pubitemid 26192194)
46. Erdogdu Ö, Nathanson D., Sjöholm Å et al. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Molecular and Cellular Endocrinology: 2010; 325 26 35
47. Kodera R., Shikata K., Kataoka H. U. et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia: 2011; 54 965 978
48. Fadini G. P., Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascular Pharmacology: 2011; 55 10 16
49. Shah Z., Pineda C., Kampfrath T. et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascular Pharmacology: 2011; 55 2 9
50. Mega C., de Lemos E. T., Vala H. et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Experimental Diabetes Research: 2011; 2011 162092
51. Liu W. J., Xie S. H., Liu Y. N. et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. Journal of Pharmacology and Experimental Therapeutics: 2012; 340 248 255
52. Alter M. L., Ott I. M., von Websky K. et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney and Blood Pressure Research: 2012; 36 119 130
53. Hendarto H., Inoguchi T., Maeda Y. et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism: 2012; 61 1422 1434
54. Mazze R. S., Bergenstal R., Ginsberg B. Intensified diabetes management: lessons from the diabetes control and complications trial. International Journal of Clinical Pharmacology and Therapeutics: 1995; 33 43 51
55. Stratton I. M., Adler A. I., Neil H. A. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal: 2000; 321 405 412 (Pubitemid 30609442)
56. Zhang H., Zhang X., Hu C. et al. Exenatide reduces urinary transforming growth factor-1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney and Blood Pressure Research: 2012; 35 483 488
57. Li L., El-Kholy W., Rhodes C. J. et al. Glucagon-like leptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia: 2005; 48 1339 1349 (Pubitemid 41186100)
58. Ruggenenti P., Perna A., Gherardi G. et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet: 1998; 352 1252 1256 (Pubitemid 28470337)
59. Apperloo A. J., De Zeeuw D., Sluiter H. E. et al. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. BMJ: 1991; 303 821 824